Improving the safety of CAR-T-cell therapy: The risk and prevention of viral infection for patients with relapsed or refractory B-cell lymphoma undergoing CAR-T-cell therapy.
Hu QianXingcheng YangTingting ZhangPing ZouYicheng ZhangWeiwei TianZekai MaoJia WeiPublished in: American journal of hematology (2024)
Chimeric antigen receptor (CAR) T-cell therapy, an innovative immunotherapeutic against relapsed/refractory B-cell lymphoma, faces challenges due to frequent viral infections. Despite this, a comprehensive review addressing risk assessment, surveillance, and treatment management is notably absent. This review elucidates immune response compromises during viral infections in CAR-T recipients, collates susceptibility risk factors, and deliberates on preventive strategies. In the post-pandemic era, marked by the Omicron variant, new and severe threats to CAR-T therapy emerge, necessitating exploration of preventive and treatment measures for COVID-19. Overall, the review provides recommendations for viral infection prophylaxis and management, enhancing CAR-T product safety and recipient survival.
Keyphrases
- cell therapy
- sars cov
- stem cells
- diffuse large b cell lymphoma
- mesenchymal stem cells
- risk assessment
- coronavirus disease
- immune response
- risk factors
- acute lymphoblastic leukemia
- acute myeloid leukemia
- public health
- multiple myeloma
- early onset
- toll like receptor
- combination therapy
- climate change
- clinical practice
- dendritic cells
- inflammatory response
- human health
- respiratory syndrome coronavirus